Eli Lilly reached an agreement with the SEC to settle charges of Foreign Corrupt Practices Act violations.
The drug company agreed to pay a civil settlement of $29.4 million and to have an independent compliance consultant conduct a 60-day review of the company’s internal controls and compliance program related to the FCPA.
